Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
321-340 of 1,782 trials

Chemotherapy-Induced Peripheral Neuropathy: Capsaicin Patch vs. Duloxetine

We are studying whether a capsaicin patch can reduce nerve pain better than duloxetine in patients with chemotherapy-induced peripheral neuropathy. The trial also looks at safety and overall quality of life improvements.

Chemotherapy Induced Peripheral Neuropathy>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyOncology

Triple-Negative Breast Cancer: Pembrolizumab and Chemotherapy Study

We are investigating whether adding pembrolizumab to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer based on their tumor-infiltrating lymphocyte levels. This study also looks at the safety and quality of life for participants.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)Standard MedicinesOncology

Severe Brain Injury: Apomorphine Treatment Study

We are investigating whether apomorphine can help patients with disorders of consciousness. The study also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness≤3 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteNeurology

Chronic Lymphocytic Leukemia: Zanubrutinib and Obinutuzumab Study

We are studying a combination of zanubrutinib and obinutuzumab for patients with untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The trial aims to see if this treatment helps achieve better remission rates compared to different schedules of drug administration.

Chronic Lymphocytic Leukemia (CLL)3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Hydroxychloroquine for Pregnancy Outcomes in Women with Antiphospholipid Antibodies

We are studying whether hydroxychloroquine can improve pregnancy outcomes for women with antiphospholipid antibodies. This research aims to help understand its potential benefits during pregnancy.

Antiphospholipid Antibodies>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesGynecology and ObstetricsInternal Medicine

Vitamin D Deficiency: Cholecalciferol Study for Postmenopausal Women

We are investigating the right dose of Cholecalciferol to help postmenopausal women with vitamin D deficiency. The study also looks at how satisfied participants are with this vitamin D supplement.

Postmenopausal Women6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Small Cell Lung Cancer: Etoposide-Free Chemotherapy with Durvalumab

We are studying a new treatment combining chemotherapy and durvalumab for patients with extensive stage small cell lung cancer. The trial aims to see how well this treatment works and how it affects patients' quality of life.

Extensive Stage Small Cell Lung Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Prostate Cancer: Estradiol and Exercise Study

We are exploring whether transdermal estradiol and resistance training can help reduce side effects like sexual dysfunction in men undergoing androgen deprivation therapy for prostate cancer. The study also looks at safety and quality of life improvements.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyUrology

Cytisine for Quitting Nicotine in E-Cigarettes and Tobacco

We are studying whether cytisine, combined with behavioral support, helps people quit using nicotine in e-cigarettes or tobacco cigarettes better than a placebo. This trial is for individuals motivated to stop using these products.

Quitting Electronic Cigarettes≤3 monthsConfirmation phase (III)Standard MedicinesPsychiatry

Atopic Dermatitis in Children: Upadacitinib vs. Dupilumab

We are studying whether upadacitinib is as safe and effective as dupilumab for children aged 2 to under 12 with moderate to severe atopic dermatitis. This trial aims to find better treatment options for young patients.

Atopic Dermatitis>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatologyPediatrics

Guselkumab for Active Psoriatic Arthritis Axial Disease

We are studying whether guselkumab can help reduce symptoms in people with active psoriatic arthritis axial disease who have not been treated before. Participants will receive either the medication or a placebo.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Insomnia in Psychiatric Patients: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep and overall well-being in patients with psychiatric disorders and chronic insomnia. This trial compares these treatments to a placebo to find the most effective option.

Psychiatric Disorders and Insomnia>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPsychiatry

Guselkumab for Pediatric Crohn’s Disease

We are studying the safety and effectiveness of guselkumab in children with moderately to severely active Crohn’s disease. This trial aims to see how well the treatment works after initial positive responses.

Crohn's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

New Surgical Treatment for Wet AMD: Vitrectomy and TPA

We are studying a new surgical approach for people with submacular hemorrhage caused by wet AMD. This trial compares it to the standard treatment to see if it improves vision and eye health.

Exudative Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Bronchiectasis: Comparing Antibiotic Treatments for PA Infection

We are studying two antibiotic regimens to see which is more effective for adults with bronchiectasis and early Pseudomonas aeruginosa infections. This research may help improve treatment options for these patients.

Bronchiectasis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Recurrent Pericarditis in Children: Anakinra vs. Steroids

We are studying whether Anakinra is more effective than steroids for controlling recurrent pericarditis in children who haven't responded to other treatments. This trial aims to help improve care for young patients facing this condition.

Pericarditis3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyRheumatology

Chronic Open-Angle Glaucoma: Preservative-Free Bimatoprost Eye Drops

We are comparing a new preservative-free eye drop to a standard treatment for patients with chronic open-angle glaucoma or ocular hypertension. The goal is to see if the new formulation is effective and safe for managing eye pressure.

Chronic Open-angle GlaucomaOcular Hypertension3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Chronic Migraine: Dysport Treatment Study

We are studying whether Dysport can help reduce the number of migraine days in adults with chronic migraines. The trial will also look at its safety and overall effectiveness compared to a placebo.

Chronic Migraine1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNeurology

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology